BioArctic AB (publ) (BRCTF)
USD 15.67
(0.0%)
USD 15.67
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 256.69 Million SEK | 1571.68% |
| 2022 | -17.44 Million SEK | 87.52% |
| 2021 | -139.72 Million SEK | -64.36% |
| 2020 | -85.01 Million SEK | -175.54% |
| 2019 | 112.53 Million SEK | -76.98% |
| 2018 | 488.79 Million SEK | 2433.4% |
| 2017 | 19.29 Million SEK | -74.15% |
| 2016 | 74.63 Million SEK | 1440.69% |
| 2015 | 4.84 Million SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -75.43 Million SEK | -3.75% |
| 2024 Q1 | -73.09 Million SEK | 8.23% |
| 2023 Q3 | 131.01 Million SEK | 229.88% |
| 2023 Q4 | -79.65 Million SEK | -160.8% |
| 2023 Q2 | -100.86 Million SEK | -133.56% |
| 2023 Q1 | 300.58 Million SEK | 595.54% |
| 2023 FY | 256.69 Million SEK | 1571.68% |
| 2022 Q3 | 132.45 Million SEK | 389.2% |
| 2022 FY | -17.44 Million SEK | 87.52% |
| 2022 Q4 | -60.65 Million SEK | -145.8% |
| 2022 Q2 | -45.79 Million SEK | -3.6% |
| 2022 Q1 | -44.2 Million SEK | -12.32% |
| 2021 FY | -139.72 Million SEK | -64.36% |
| 2021 Q2 | -33.81 Million SEK | -16.02% |
| 2021 Q3 | -37.4 Million SEK | -10.64% |
| 2021 Q4 | -39.35 Million SEK | -5.21% |
| 2021 Q1 | -29.14 Million SEK | 3.37% |
| 2020 Q1 | 3.79 Million SEK | 118.0% |
| 2020 Q4 | -30.15 Million SEK | -45.64% |
| 2020 Q3 | -20.7 Million SEK | 45.42% |
| 2020 Q2 | -37.94 Million SEK | -1100.0% |
| 2020 FY | -85.01 Million SEK | -175.54% |
| 2019 Q4 | -21.07 Million SEK | -100.51% |
| 2019 Q2 | 126.78 Million SEK | 631.39% |
| 2019 Q1 | 17.33 Million SEK | -95.97% |
| 2019 FY | 112.53 Million SEK | -76.98% |
| 2019 Q3 | -10.51 Million SEK | -108.29% |
| 2018 Q2 | 6.44 Million SEK | -65.9% |
| 2018 FY | 488.79 Million SEK | 2433.4% |
| 2018 Q4 | 430.32 Million SEK | 1199.08% |
| 2018 Q3 | 33.12 Million SEK | 413.88% |
| 2018 Q1 | 18.9 Million SEK | 28.31% |
| 2017 Q1 | 1.46 Million SEK | -98.49% |
| 2017 FY | 19.29 Million SEK | -74.15% |
| 2017 Q2 | 2.47 Million SEK | 68.48% |
| 2017 Q4 | 14.73 Million SEK | 2279.97% |
| 2017 Q3 | 619 Thousand SEK | -74.99% |
| 2016 Q1 | -6.25 Million SEK | 0.0% |
| 2016 FY | 74.63 Million SEK | 1440.69% |
| 2016 Q4 | 97.33 Million SEK | 1054.81% |
| 2016 Q3 | -10.19 Million SEK | 9.33% |
| 2016 Q2 | -11.24 Million SEK | -79.77% |
| 2015 FY | 4.84 Million SEK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 18408.962% |
| CSL Limited | 3.7 Billion USD | 93.066% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 457.577% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -5122.785% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | 98175.85% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 1538.281% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | -213.603% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 16811.055% |
| Mesoblast Limited | -84.14 Million USD | 405.049% |
| Marizyme, Inc. | -34.08 Million USD | 853.054% |
| Genus plc | 6.4 Million USD | -3910.781% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | -2534.756% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | 27660.18% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 3174.132% |
| ContraFect Corporation | -56.88 Million USD | 551.212% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | 5735.685% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| IMV Inc. | -38.67 Million USD | 763.77% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | 9431.335% |
| MultiCell Technologies, Inc. | -722.81 USD | 35512890.36% |
| Accustem Sciences Inc. | -3.74 Million USD | 6951.609% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 535.142% |
| EV Biologics, Inc. | -483.06 Thousand USD | 53238.106% |
| Q BioMed Inc. | -3.44 Million USD | 7549.756% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | -7151.13% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | 9869.281% |
| Biomind Labs Inc. | -1 Million USD | 25524.845% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | 3961.153% |
| Skye Bioscience, Inc. | -13.67 Million USD | 1977.514% |
| SQZ Biotechnologies Company | -75.82 Million USD | 438.53% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | 857104.541% |
| Arch Therapeutics, Inc. | -5.04 Million USD | 5188.529% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | 9105.065% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 1717.481% |
| Neon Bloom, Inc. | -389.57 Thousand USD | 65990.597% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | -4.87 Million USD | 5360.533% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | 13021.858% |
| Curative Biotechnology, Inc. | -1.93 Million USD | 13382.038% |
| GB Sciences, Inc. | -1.42 Million USD | 18170.283% |
| Alpha Cognition Inc. | -9.7 Million USD | 2744.762% |
| argenx SE | -425.04 Million USD | 160.391% |
| HST Global, Inc. | -140.9 Thousand USD | 182269.8% |
| Halberd Corporation | -75.05 Thousand USD | 342125.316% |
| Enzolytics Inc. | -2.14 Million USD | 12045.737% |
| Resverlogix Corp. | -12.74 Million USD | 2113.413% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | 8201.888% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 562.438% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 566.944% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | 24687.165% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | 8947.566% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | 8892.428% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | 13868.19% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | 16352.837% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | 7638.666% |
| AVAX Technologies, Inc. | 6.69 Million USD | -3735.27% |
| ONE Bio Corp. | 13.68 Million USD | -1776.176% |
| Zenith Capital Corp. | -8.94 Million USD | 2970.29% |
| Genscript Biotech Corporation | -415.79 Million USD | 161.735% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | 1473551.581% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | 10554.455% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | 149765.144% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 12904.046% |
| Wesana Health Holdings Inc. | -1.12 Million USD | 22918.796% |
| Agentix Corp. | -1.37 Million USD | 18812.512% |
| Adynxx, Inc. | - USD | -Infinity% |
| Kadimastem Ltd | -3.04 Million USD | 8543.056% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | 26184.977% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | -1.25 Million USD | 20537.102% |
| BioStem Technologies, Inc. | -7.77 Million USD | 3399.795% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | 141538.686% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | 19321.51% |
| LadRx Corporation | -3.82 Million USD | 6813.261% |
| Cell Source, Inc. | -4.32 Million USD | 6034.554% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | 61881.703% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | 37466.621% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | 37466.621% |
| NovAccess Global Inc. | -2.46 Million USD | 10505.958% |
| Affymax, Inc. | -15.04 Million USD | 1806.035% |
| Itoco Inc. | -919.14 Thousand USD | 28027.193% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | 6156.275% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | 23039.231% |
| CytoDyn Inc. | -18.05 Million USD | 1521.475% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | 1019925.189% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | 116735.92% |
| Qrons Inc. | -643.67 Thousand USD | 39978.697% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | 45554.143% |
| SYBLEU INC | -149.18 Thousand USD | 172167.301% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | -2.22 Million USD | 11611.387% |
| Rebus Holdings, Inc. | -664 Thousand USD | 38758.133% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | 14232.422% |
| Mobile Lads Corp. | -554.55 Thousand USD | 46387.981% |
| International Stem Cell Corporation | -663 Thousand USD | 38816.44% |
| Bioxytran, Inc. | -3.82 Million USD | 6819.375% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | 487732.979% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | 1262096.067% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 807.798% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | 15964.648% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | -735.83 Thousand USD | 34984.179% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | 8351.045% |
| Neutra Corp. | -229.48 Thousand USD | 111954.318% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 1563.538% |
| PureTech Health plc | -146.19 Million USD | 275.576% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 1294.4% |
| IXICO plc | -1.43 Million USD | 17962.909% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 2804.562% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 310.737% |
| CSL Limited | 3.81 Billion USD | 93.266% |
| Cellectis S.A. | -108.85 Million USD | 335.804% |